AltruBio Taiwan Inc.
Update：2023/06/12
Industries
Main Industry
Health Care
Main Product/Service
AltruBio’s lead drug candidates are PSGL-1 agonist antibodies serving as immune checkpoint enhancers: ALTB-168, their first-generation molecule, has demonstrated safety and efficacy in Phase 1 and Phase 2 trials; and the next-generation ALTB-268, a tetrav
Founded Year
2020
Unified Business No.
82948968
Status
Active
Number of Employees
0
Total Paid-in
Capital
25,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AltruBio Inc. is a clinical-stage biotechnology company headquartered in San Francisco with an R&D center in Taipei. They specialize in developing first-in-class immune checkpoint enhancers (ICEs) for immunological and inflammatory diseases, backed by a w
